TRODELVY 200mg

TRODELVY dosing and administration1

Method of administration

First infusion Subsequent infusions
Infusion period 3 hours 1–2 hours
(if prior infusions were tolerated)
Observation period Observe patients during the infusion and for ≥30 min after

The infusion rate of TRODELVY should be slowed down or infusion interrupted if the patient develops an infusion-related reaction. Grade ≥3 infusion reactions occurred in 1.9% of patients receiving TRODELVY (n=7/366).

REFERENCES:

  1. TRODELVY (sacituzumab govitecan) Summary of Product Characteristics, February 2023.